Department of Genetics, Harvard Medical School, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.
Sci Signal. 2011 Oct 25;4(196):rs10. doi: 10.1126/scisignal.2002029.
Characterizing the extent and logic of signaling networks is essential to understanding specificity in such physiological and pathophysiological contexts as cell fate decisions and mechanisms of oncogenesis and resistance to chemotherapy. Cell-based RNA interference (RNAi) screens enable the inference of large numbers of genes that regulate signaling pathways, but these screens cannot provide network structure directly. We describe an integrated network around the canonical receptor tyrosine kinase (RTK)-Ras-extracellular signal-regulated kinase (ERK) signaling pathway, generated by combining parallel genome-wide RNAi screens with protein-protein interaction (PPI) mapping by tandem affinity purification-mass spectrometry. We found that only a small fraction of the total number of PPI or RNAi screen hits was isolated under all conditions tested and that most of these represented the known canonical pathway components, suggesting that much of the core canonical ERK pathway is known. Because most of the newly identified regulators are likely cell type- and RTK-specific, our analysis provides a resource for understanding how output through this clinically relevant pathway is regulated in different contexts. We report in vivo roles for several of the previously unknown regulators, including CG10289 and PpV, the Drosophila orthologs of two components of the serine/threonine-protein phosphatase 6 complex; the Drosophila ortholog of TepIV, a glycophosphatidylinositol-linked protein mutated in human cancers; CG6453, a noncatalytic subunit of glucosidase II; and Rtf1, a histone methyltransferase.
描述信号转导网络的范围和逻辑对于理解生理和病理生理环境中的特异性至关重要,例如细胞命运决定以及致癌和化疗耐药的机制。基于细胞的 RNA 干扰 (RNAi) 筛选可推断出大量调节信号通路的基因,但这些筛选方法不能直接提供网络结构。我们通过将平行的全基因组 RNAi 筛选与串联亲和纯化-质谱蛋白质-蛋白质相互作用 (PPI) 作图相结合,描述了一个围绕经典受体酪氨酸激酶 (RTK)-Ras-细胞外信号调节激酶 (ERK) 信号通路的综合网络。我们发现,在所有测试条件下,只有一小部分 PPI 或 RNAi 筛选命中被分离,而且大多数是已知的经典途径组成部分,这表明核心经典 ERK 途径的大部分是已知的。由于大多数新鉴定的调节剂可能是细胞类型和 RTK 特异性的,因此我们的分析为理解如何在不同环境中调节这条具有临床相关性的通路提供了资源。我们报告了几种先前未知的调节剂在体内的作用,包括 CG10289 和 PpV,它们是丝氨酸/苏氨酸蛋白磷酸酶 6 复合物两个成分的果蝇同源物;人类癌症中突变的糖磷脂酰肌醇连接蛋白 TepIV 的果蝇同源物;葡萄糖苷酶 II 的非催化亚基 CG6453;以及组蛋白甲基转移酶 Rtf1。